Strategic Pharmaceutical
Distribution & Marketing

We act as the local commercial arm for manufacturers entering Uzbekistan, the wider CIS, the Caucasus and the GCC: product registration, import and customs, warehousing with cold chain, a medical representative network, pharmacovigilance and marketing. The manufacturer keeps ownership of the brand and the marketing authorisation.

22 countries. Uzbekistan, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan, Russia, Belarus and Ukraine in the CIS; Azerbaijan, Armenia and Georgia in the Caucasus; the UAE, Saudi Arabia, Qatar, Kuwait, Oman and Bahrain in the GCC; Italy, Poland, Czech Republic and Slovenia in Europe; plus Turkey.

A standard dossier review runs about 9 to 14 months from submission, depending on the product category and the completeness of the CTD dossier. Since October 2025 a recognition procedure is available for products already approved by reference regulators, which shortens the timeline substantially. Detailed breakdown is in our guide on drug registration in Uzbekistan.

Usually yes. Exclusivity is what justifies investment into registration, the medical representative team and promotional activity. Terms, targets and territory are fixed in the distribution agreement before the first shipment.

The main items are dossier preparation and registration fees, the first commercial shipment, promotional materials and the field force. Costs differ strongly by category and by how many countries you enter at once, so we prepare a per-market model before any commitment. Our cost guide walks through the structure.

Intellia F.Z.E. is registered in Dubai, United Arab Emirates (Unit 901, Iris Bay, Business Bay). The group also includes Sorrento Pharm, which runs distribution operations in Uzbekistan, and Laxisam Pharmaceuticals, a GMP-certified manufacturing site in Tashkent.